Document Detail

Statin use and reduced cancer-related mortality.
MedLine Citation:
PMID:  23134381     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: A reduction in the availability of cholesterol may limit the cellular proliferation required for cancer growth and metastasis. We tested the hypothesis that statin use begun before a cancer diagnosis is associated with reduced cancer-related mortality.
METHODS: We assessed mortality among patients from the entire Danish population who had received a diagnosis of cancer between 1995 and 2007, with follow-up until December 31, 2009. Among patients 40 years of age or older, 18,721 had used statins regularly before the cancer diagnosis and 277,204 had never used statins.
RESULTS: Multivariable-adjusted hazard ratios for statin users, as compared with patients who had never used statins, were 0.85 (95% confidence interval [CI], 0.83 to 0.87) for death from any cause and 0.85 (95% CI, 0.82 to 0.87) for death from cancer. Adjusted hazard ratios for death from any cause according to the defined daily statin dose (the assumed average maintenance dose per day) were 0.82 (95% CI, 0.81 to 0.85) for a dose of 0.01 to 0.75 defined daily dose per day, 0.87 (95% CI, 0.83 to 0.89) for 0.76 to 1.50 defined daily dose per day, and 0.87 (95% CI, 0.81 to 0.91) for higher than 1.50 defined daily dose per day; the corresponding hazard ratios for death from cancer were 0.83 (95% CI, 0.81 to 0.86), 0.87 (95% CI, 0.83 to 0.91), and 0.87 (95% CI, 0.81 to 0.92). The reduced cancer-related mortality among statin users as compared with those who had never used statins was observed for each of 13 cancer types.
CONCLUSIONS: Statin use in patients with cancer is associated with reduced cancer-related mortality. This suggests a need for trials of statins in patients with cancer.
Sune F Nielsen; Børge G Nordestgaard; Stig E Bojesen
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The New England journal of medicine     Volume:  367     ISSN:  1533-4406     ISO Abbreviation:  N. Engl. J. Med.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-08     Completed Date:  2012-11-19     Revised Date:  2013-10-11    
Medline Journal Info:
Nlm Unique ID:  0255562     Medline TA:  N Engl J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1792-802     Citation Subset:  AIM; IM    
Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cardiovascular Diseases / complications,  epidemiology
Cause of Death
Denmark / epidemiology
Diabetes Complications / epidemiology
Diabetes Mellitus / epidemiology
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Middle Aged
Neoplasms / complications,  mortality*,  prevention & control
Proportional Hazards Models
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors
Comment In:
Internist (Berl). 2013 Sep;54(9):1152-4   [PMID:  23963278 ]
N Engl J Med. 2013 Feb 7;368(6):575-6   [PMID:  23388015 ]
N Engl J Med. 2013 Feb 7;368(6):576-7   [PMID:  23388012 ]
N Engl J Med. 2013 Feb 7;368(6):576   [PMID:  23388016 ]
N Engl J Med. 2013 Feb 7;368(6):574-5   [PMID:  23388014 ]
N Engl J Med. 2013 Feb 7;368(6):574   [PMID:  23388013 ]
N Engl J Med. 2012 Nov 8;367(19):1848-50   [PMID:  23134387 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  "If I had only known"--on choice and uncertainty in the ICU.
Next Document:  Reduced mortality with hospital pay for performance in England.